Mass General Cancer Center Chiefs’ Update
We hope that you and your family are staying well. During this time when we are unable to gather in person, it is important to us that we stay connected with our closest friends and supporters.
Please join us for the Mass General Cancer Center Chiefs’ Update. This virtual event will feature an update from our leadership team on the Cancer Center’s research and operations. Dr. Justin Gainor will also share an update on a recent study conducted at Mass General, focused on COVID-19 vaccines and their safety and effectiveness in patients with cancer.
This is a view-only webinar, no video or microphone capabilities are needed to participate.
Please contact the Mass General Development Office at MGHevents@partners.org with any questions.
Mara G. Bloom, JD, MS
Vice President, Mass General Cancer Center
Mara Bloom serves as vice president for the Mass General Cancer Center. She has oversight for the Cancer Center’s program development, clinical operations, patient experience, clinical trials and research programs, strategic planning, marketing and communications, regional networks, and international affiliations. Previously Mara held several positions at New York-Presbyterian Hospital, including director of the Oncology Service Line, director of Planning and director of Performance Improvement. Mara has a JD from the University of Miami School of Law and a MS in Management from the New York University Wagner School of Public Service. She currently serves as a board member for National Comprehensive Cancer Network and the co-director of the Harvard Medical School Master’s in Clinical Service Operations Degree Program.
Justin F. Gainor, MD
Director, Center for Thoracic Cancers
Director, Targeted Immunotherapy, Henri and Belinda Termeer Center for Targeted Therapies
Dr. Justin Gainor is director of the Center for Thoracic Cancers at the Mass General Cancer Center and an Associate Professor of Medicine at Harvard Medical School. Dr. Gainor received his BA from Johns Hopkins University and his MD from Harvard Medical School. He has been with Mass General as an intern, resident and fellow. He joined Mass General’s faculty in 2013 and is recognized for combining cutting-edge translational research with clinical care in an innovative and compassionate manner.
Dr. Gainor’s major research interests center around two themes: targeted therapy and immunotherapy. He has led multiple clinical trials evaluating novel targeted therapies for patients with oncogene-driven lung cancers. In parallel, he has played an active role in uncovering the molecular mechanisms of resistance to targeted therapies in lung cancer. More recently, Dr. Gainor has worked to transfer the same clinical-translational research framework pioneered in targeted therapies to the immunotherapy setting. In 2018, he was appointed director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies. His current work is focused on investigating the role of novel immunotherapies and immunotherapy combinations in patients with non-small cell lung cancer. He is also leading a multi-institutional effort to identify new biomarkers of response and resistance to immune checkpoint inhibitors.
Dr. Gainor is currently the co-leader of a Stand Up to Cancer/Mark Foundation Lung Cancer Dream Team. He has more than 88 original research articles or reviews that have appeared in high-impact journals, including the New England Journal of Medicine, Journal of Clinical Oncology, Cancer Discovery, JCO Precision Oncology and Clinical Cancer Research. He currently sits on multiple editorial boards, including the Journal of Clinical Oncology and Clinical Lung Cancer.
Daniel A. Haber, MD, PhD
Director, Mass General Cancer Center
Dr. Daniel Haber is director of the Mass General Cancer Center and the Kurt Isselbacher Professor of Oncology at Harvard Medical School. He received his MD and PhD degrees at Stanford in 1983, completed an internal medicine residency at Mass General, clinical oncology training at Dana-Farber Cancer Institute and a postdoctoral research fellowship at MIT. He joined the faculty of Harvard Medical School in 1991.
Dr. Haber’s numerous awards include a MERIT Award from the National Cancer Institute, a Dream Team Award from the Prostate Cancer Foundation, a Dream Team Award from Stand Up To Cancer and the Richard and Linda Rosenthal Memorial Award from the American Association for Cancer Research (AACR). He was appointed to the Howard Hughes Medical Institute in 2008, and he was elected to the Institute of Medicine in 2009, the American Academy of Arts and Sciences in 2011, and the National Academy of Sciences in 2018.
Dr. Haber’s research has focused primarily in the field of cancer genetics, resulting in discoveries on the origin of the pediatric kidney cancer Wilms tumor, genetic predispositions to breast cancer and mutations that define a subset of “non-smoker” lung cancers that are uniquely sensitive to targeted new therapies. In collaboration with Mass General bioengineer Mehmet Toner, PhD, Dr. Haber’s laboratory has developed a novel technology for isolating rare CTCs from the blood of cancer patients — a tool that may have profound implications for early diagnosis of cancer and for non-invasive molecular profiling of cancers during therapy.
David P. Ryan, MD
Clinical Director, Mass General Cancer Center
Dr. Dave Ryan is the Shelby Memorial Professor of Medicine in the Field of Cancer Therapeutics at Harvard Medical School. He became chief of the Division of Hematology/Oncology at Mass General in October 2012. He is the clinical director of Mass General Cancer Center and co-associate director for clinical science for the Dana-Farber/Harvard Cancer Center.
Dr. Ryan is an authority on the treatment of gastrointestinal cancers as well as the design and conduct of Phase I and II clinical trials for patients with those cancers. His expertise has been recognized by membership in leading national committees, including clinical task forces for the National Cancer Institute and the National Comprehensive Cancer Center Network.
Dr. Ryan received his hematology and oncology training through the combined Mass General/Dana-Farber Cancer Institute fellowship program in 1996. He graduated in Medicine from Columbia College of Physicians and Surgeons in New York in 1992 and remained there for his internship and medical residency. He is a member of the American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO). Dr. Ryan sits on the editorial board of Clinical Cancer Research and The Oncologist. He is the author of more than 100 peer-reviewed manuscripts and a co-author of Living with Cancer.
Related ContentCancer Center